Novel Predictors of Intravenous Immunoglobulin Resistance in Chinese Children with Kawasaki Disease

Pediatric Research

Volumn 32, Issue 8, 2013, Pages e319-e323

  Fu, Pei Pei ^a,b   Du, Zhong Dong ^a,b   Pan, Yue Song ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Intravenous immunoglobulin; Kawasaki disease; Prediction; Resistance

Indexed keywords

ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN;

CHILD; CHINESE; FEMALE; FEVER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHINA; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; LOGISTIC MODELS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84880589886     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1097/INF.0b013e31828e887f     Document Type: Article

References (24)

1. Newburger JW, Takahashi M, Gerber MA, et al. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708-1733
2. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:E78
3. Kaneko K, Yoshimura K, Ohashi A, et al. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr Cardiol. 2011;32:1106-1109
4. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606-2612
5. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149:237-240
6. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153:117-121
7. Japanese Circulation Society Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. Pediatr Int. 2005;47:711-732
8. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002;86:286-290
9. de Zorzi A, Colan SD, Gauvreau K, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998;133:254-258
10. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166:131-137
11. Kuo HC, Yang KD, Liang CD, et al. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. Pediatr Allergy Immunol. 2007;18:354-359
12. Abe J, Ebata R, Jibiki T, et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol. 2008;122:1008-1013.e8
13. Heaton P, Wilson N, Nicholson R, et al. Kawasaki disease in New Zealand. J Paediatr Child Health. 2006;42:184-190
14. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112(3 Pt 1):495-501
15. Nakamura Y, Yashiro M, Uehara R, et al. Increasing incidence of Kawasaki disease in Japan: nationwide survey. Pediatr Int. 2008;50:287-290
16. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol. 2010;20:302-307
17. Sleeper LA, Minich LL, McCrindle BM, et al. Pediatric Heart Network Investigators. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158:831-835.e3
18. Miura M, Ohki H, Tsuchihashi T, et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch Dis Child. 2004;89:776-780
19. Miura M, Kohno K, Ohki H, et al. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr. 2008;167:1119-1123
20. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005;90:1096-1097
21. Kobayashi T, Saji T, Otani T, et al. RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613-1620
22. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158:644-649.e1
23. Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011;124:2822-2828
24. Lee TJ, Kim KH, Chun JK, et al. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J. 2008;49:714-718